E1A11; Randomized Phase III Trial of Bortezomib Lenalidomide and Dexamethasone (VRd) Versus Carfilzomib Lenalidomide Dexamethasone (CRd) Followed by Limited or Indefinite Lenalidomide Maintenance in Patients With Newly Diagnosed Symptomatic Multiple Myeloma
Are you eligible to participate in this study?
You may be eligible for this study if you meet the following criteria:
Conditions: Multiple Myeloma
Age: Between 18 - 100 Years
Gender: Male or Female
To be eligible for this trial, subjects must be 18 years of age or older with diagnosed symptomatic standard risk multiple-myeloma. For a full list of eligibility criteria and additional trial information please visit clinicaltrials.gov